Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Metamizole (dipyrone) versus ibuprofen for post-cesarean analgesia in women with preeclampsia with severe features: a quadruple-blind, randomized, active-comparator trial.

Created on 01 Nov 2026

Authors

Ana Carolina Barbosa Pordeus, Leila Katz, Marina Torres Maia, Maria Eduarda Bezerra Figueiredo, Thalita Lustosa de Oliveira Avelino Lopes, Alexandre Magno Delgado, Melania Maria Ramos de Amorim

Published in

American journal of obstetrics & gynecology MFM. Pages 102162. Oct 31, 2026. Epub Oct 31, 2026.

Abstract

Adequate analgesia after cesarean delivery is a priority in women with preeclampsia, in whom opioid-sparing strategies are desirable. Nonsteroidal anti-inflammatory drugs (NSAIDs) were historically avoided in hypertensive disorders of pregnancy because of a presumed effect on blood pressure, but randomized trials and meta-analyses have since shown no clinically meaningful blood-pressure effect, and current guidance supports their postpartum use when otherwise appropriate. Metamizole (dipyrone) is a non-opioid analgesic widely used in Brazil, Latin America, and parts of Europe, but its regulatory status varies internationally. It is not approved in the United States, and agranulocytosis is a recognized rare but potentially serious adverse reaction. European regulatory guidance also advises against its use during breastfeeding. No randomized trial has directly compared metamizole with an NSAID after cesarean delivery in women with preeclampsia.
To compare metamizole and ibuprofen for analgesic effectiveness and short-term safety, with particular attention to blood pressure trajectory and renal function, after cesarean delivery in women with preeclampsia with severe features.
Quadruple-blind (participant, care provider, investigator, outcome assessor), randomized, active-comparator, phase 4 trial at a tertiary maternity hospital in northeastern Brazil. Seventy-four women received oral metamizole 1 g or ibuprofen 400 mg every 6 hours for up to 5 days, with intravenous tramadol available as rescue analgesia. Co-primary outcomes, as prospectively registered, were postoperative pain-categorized as mild, moderate, or severe by visual analogue scale (VAS)-and acute kidney injury (AKI). Continuous VAS, the D1-to-D2 mean reduction in VAS, the clinically interpretable threshold VAS ≥4, the Faces Pain Scale-Revised, peri-incisional pressure pain thresholds by algometry, rescue analgesia, serial blood pressure, hypertensive episodes, laboratory values, satisfaction, and length of stay were secondary or supportive outcomes. Effects were estimated with risk differences, risk ratios, exact tests, Hodges-Lehmann differences, standardized effect sizes with Holm correction, and linear mixed-effects models.
Thirty-eight women were allocated to metamizole and 36 to ibuprofen. The registered three-category pain distribution did not differ between groups on day 1 (exact P=.45) or day 2 (exact P=.55). Median VAS was 4 (IQR 2-5) in both groups on day 1 and 2 (IQR 2-4) versus 3 (IQR 2-4) on day 2; the mean D1-to-D2 VAS reduction was 1.0 (SD 2.1) versus 0.6 (SD 2.4), with a mean between-group difference in reduction of 0.36 points (95% CI -0.70 to 1.42; P=.50). Rescue analgesia on day 1 was required by 18.4% versus 38.9% (risk difference -20.5 percentage points, 95% CI -39.1 to 0.1). AKI occurred in 3 of 38 (7.9%) versus 1 of 36 (2.8%) (risk ratio 2.84; 95% CI 0.31-26.08; Fisher P=.62; risk difference +5.1 percentage points, 95% CI -7.4 to 18.2). Linear mixed-effects models showed no group-by-time interaction for systolic (P=.14) or diastolic (P=.18) blood pressure; robust GEE sensitivity analyses were concordant. Severe hypertensive episodes were rare in both arms.
In this randomized trial, no clear between-group difference was detected in postoperative pain or blood-pressure trajectory. The trial was not designed as an equivalence or non-inferiority study. AKI was numerically more frequent with metamizole, but the estimate was highly imprecise; comparative renal safety remains uncertain and requires adequately powered studies.

PMID:
42966477
Bibliographic data and abstract were imported from PubMed on 01 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 33
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement